Condition

Non-alcoholic Steatohepatitis

ClinicalTrials.gov condition label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 15 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials15
Recruiting4
Common interventions18
Lead sponsors shown14
Advertisement

Clinical trials

15 shown
Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled TrialNCT06138821 · 2025-06-24
RECRUITING
Endoscopic Ultrasound Shear Wave Elastography in Patients With Non-alcoholic Fatty Liver DiseaseNCT05728697 · 2021-06-01
RECRUITING
Prognostic Significance of Fatty Liver Disease in Bariatric PatientsNCT03535142 · 2018-08-15
RECRUITING
European Paediatric Non-Alcoholic Fatty Liver Disease Registry (EU-PNAFLD)NCT04190849 · 2017-11-14
RECRUITING
Reducing Non-Alcoholic SteatohepatitisNCT06519448 · 2024-04-01
ENROLLING_BY_INVITATION
Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 AnalogueNCT05751720 · 2023-10-01
UNKNOWN
A Randomised, Open-Label Study to Evaluate the Relative and Absolute Bioavailability of Cotadutide in Healthy SubjectsNCT05294458 · 2022-03-28
COMPLETED
Plant Stanols and Liver Inflammation in Overweight and Obese ChildrenNCT04783116 · 2021-03-15
UNKNOWN
To Evaluate the Effect of Nesinaact on Non-alcoholic Steatohepatitis Through MRI and Liver Fibroscan in Patients With Type 2 DiabetesNCT03950505 · 2020-05-29
UNKNOWN
A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese SubjectsNCT04142424 · 2019-10-28
COMPLETED
A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes MellitusNCT03969719 · 2019-07-18
COMPLETED
Assessment of the Safety and Effect of SAR425899 Versus Placebo for the Treatment of Non-alcoholic Fatty Liver DiseaseNCT03437720 · 2019-05-23
WITHDRAWN
Technical Validation of MR Biomarkers of Obesity-Associated NAFLDNCT03674528 · 2018-05-04
COMPLETED
Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal HypertensionNCT02960204 · 2016-10-17
COMPLETED
Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive ProceduresNCT00678587 · 2008-06-01
TERMINATED

Common interventions

Mapped drugs appearing in these trials

Shared trial participation only; not evidence of efficacy or approval.

Trial status mix

COMPLETED5
RECRUITING4
UNKNOWN3
ENROLLING_BY_INVITATION1
TERMINATED1
WITHDRAWN1

Phase mix

NA4
PHASE24
PHASE13
PHASE31
PHASE41
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.